CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer.
Saved in:
| Title: | CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. |
|---|---|
| Authors: | Kalimutho M; QIMR Berghofer Medical Research Institute, Herston, Qld, Australia murugan.kalimutho@qimrberghofer.edu.au kumkum.khanna@qimrberghofer.edu.au.; School of Natural Sciences, Griffith University, Nathan, Qld, Australia., Sinha D; QIMR Berghofer Medical Research Institute, Herston, Qld, Australia.; School of Natural Sciences, Griffith University, Nathan, Qld, Australia., Jeffery J; QIMR Berghofer Medical Research Institute, Herston, Qld, Australia., Nones K; QIMR Berghofer Medical Research Institute, Herston, Qld, Australia.; Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Qld, Australia., Srihari S; Computational Systems Biology Laboratory, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Qld, Australia., Fernando WC; QIMR Berghofer Medical Research Institute, Herston, Qld, Australia., Duijf PH; University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, Qld, Australia., Vennin C; Cancer Division, Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.; Faculty of Medicine, St Vincent's Clinical School, University of NSW, Sydney, NSW, Australia., Raninga P; QIMR Berghofer Medical Research Institute, Herston, Qld, Australia., Nanayakkara D; QIMR Berghofer Medical Research Institute, Herston, Qld, Australia., Mittal D; QIMR Berghofer Medical Research Institute, Herston, Qld, Australia., Saunus JM; QIMR Berghofer Medical Research Institute, Herston, Qld, Australia.; Centre for Clinical Research, The University of Queensland, Herston, Qld, Australia., Lakhani SR; Centre for Clinical Research, The University of Queensland, Herston, Qld, Australia.; School of Medicine, The University of Queensland, Herston, Qld, Australia.; Pathology Queensland, The Royal Brisbane and Women's Hospital, Herston, Qld, Australia., López JA; QIMR Berghofer Medical Research Institute, Herston, Qld, Australia.; School of Natural Sciences, Griffith University, Nathan, Qld, Australia., Spring KJ; Liverpool Clinical School, University of Western Sydney, Liverpool, NSW, Australia.; Ingham Institute, Liverpool Hospital, Liverpool, NSW, Australia.; South Western Sydney Clinical School, University of New South Wales, Liverpool, NSW, Australia., Timpson P; Cancer Division, Garvan Institute of Medical Research and The Kinghorn Cancer Centre, Sydney, NSW, Australia.; Faculty of Medicine, St Vincent's Clinical School, University of NSW, Sydney, NSW, Australia., Gabrielli B; University of Queensland Diamantina Institute, Translational Research Institute, The University of Queensland, Brisbane, Qld, Australia.; Mater Research Institute, Translational Research Institute, The University of Queensland, Brisbane, Qld, Australia., Waddell N; QIMR Berghofer Medical Research Institute, Herston, Qld, Australia., Khanna KK; QIMR Berghofer Medical Research Institute, Herston, Qld, Australia murugan.kalimutho@qimrberghofer.edu.au kumkum.khanna@qimrberghofer.edu.au. |
| Source: | EMBO molecular medicine [EMBO Mol Med] 2018 Sep; Vol. 10 (9). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: EMBO Press Country of Publication: Germany NLM ID: 101487380 Publication Model: Print Cited Medium: Internet ISSN: 1757-4684 (Electronic) Linking ISSN: 17574676 NLM ISO Abbreviation: EMBO Mol Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
